Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

Oncology has recently undergone a revolutionary change with widespread adoption of immunotherapy for many cancers. Immunotherapy using monoclonal antibodies against checkpoint molecules, including programmed death (PD)-1, PD ligand (PD-L)1, and cytotoxic T lymphocyte-associated antigen (CTLA)-4, is...

Full description

Saved in:

Bibliographic Details
Published in:	Trends in immunology Vol. 40; no. 6; pp. 511 - 523
Main Authors:	Pauken, Kristen E., Dougan, Michael, Rose, Noel R., Lichtman, Andrew H., Sharpe, Arlene H.
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.06.2019 Elsevier Limited
Subjects:	Adaptive immunity Antigens Autoimmune diseases autoimmunity Cancer immunotherapy Cancer therapies checkpoint blockade Clinical trials Cloning Cytotoxicity Disease Etiology Hepatitis Immune checkpoint Immune system immune-related adverse events Immunoglobulins Immunotherapy Inflammatory bowel disease Inflammatory diseases Lymphocytes Lymphocytes T Melanoma Monoclonal antibodies Oncology tolerance Viral infections checkpoint blockade autoimmunity tolerance cancer immunotherapy immune-related adverse events
ISSN:	1471-4906, 1471-4981, 1471-4981
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!